Several studies have shown that increased expression of checkpoint inhibitors on tumor cells following epigenetic treatment enhances responses to ICB therapy [220, 223], for instance, a study from Woods et al. showed that treatment with HDACis in melanoma-bearing mice elevated PD-L1 and PD-L2 in tumor cells as a result of increased histone acetylation, and combined HDACi and anti-PD-1 therapy slowed tumor progression and increased survival compared to single-agent therapy [223]. This evidence concerns the gene CD274 and neoplasm.